Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264877 | 1.00 | CYP51A1 (0.35) | CYP51A1RECQLCYP3A4ADRB3NAMPT | |
| SCHEMBL264642 | 0.91 | TACR1 (0.37) | CYP3A4NPC1RAB9APPARDDAO | |
| SCHEMBL263828 | 0.91 | TACR1 (0.37) | CYP3A4NPC1RAB9APPARDDAO | |
| SCHEMBL263829 | 0.91 | TACR1 (0.37) | CYP3A4NPC1RAB9APPARDDAO | |
| SCHEMBL265803 | 0.90 | CYP3A4 (0.36) | CYP51A1CYP3A4ADRB3NAMPTEP300 | |
| SCHEMBL265804 | 0.90 | CYP3A4 (0.36) | CYP51A1CYP3A4ADRB3NAMPTEP300 | |
| SCHEMBL265266 | 0.86 | DAO (0.36) | PPARDDAOEP300 | |
| SCHEMBL265265 | 0.86 | DAO (0.36) | PPARDDAOEP300 | |
| SCHEMBL265835 | 0.84 | TACR1 (0.37) | CYP3A4PPARDDAOEP300 | |
| SCHEMBL265836 | 0.84 | TACR1 (0.37) | CYP3A4PPARDDAOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| CN-102066325-A | Heteroaromatic monoamides as orexin receptor antagonists | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | CYP51A1 1662/4885RECQL 2949/4885CYP3A4 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.